EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer

Daeseong Kim, Nam Suk Sim, Seonjeong Woo, Min Hwan Kim, Choong-Kun Lee, Seung Soo Hong, Sung Hyun Kim, Ho Kyoung Hwang, Chang Moo Kang, Woo Jung Lee, Jung Hyun Jo, Taek Chung und 9 weitere

Clinical and Molecular Hepatology · 2026

DOI: 10.3350/cmh.2025.1019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Daeseong Kim und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Deoxycytidine, Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Biliary tract cancer (BTC) is a rare malignancy with poor prognosis. We investigated genomic determinants of clinical benefit from gemcitabine, cisplatin, and nab-paclitaxel (GAP) versus gemcitabine and cisplatin (GC) in advanced BTC.

Methods

Clinical and genomic data using TruSight Oncology 500 were analyzed from patients treated with GAP (N=198) or GC (N=89) as first-line therapy.

Results

With a median follow-up of 33.0 months, GAP modestly improved progression-free survival (PFS) (hazard ratio [HR] 0.764; 95% confidence interval [CI] 0.591–0.989) without significant overall survival (OS) difference compared to GC. Genomic profiling revealed frequent alterations in TP53 (35.2%), KRAS (16.4%), SMAD4 (10.5%), and TNFRSF14 (10.5%), involving RTK/RAS (44.3%), TP53 (41.8%), and PI3K (20.2%) pathways. Single-gene mutations did not predict treatment benefit. However, pathway-level analysis identified PI3K pathway activation as significantly associated with inferior PFS (HR 2.148; 95% CI 1.478–3.124) and OS (HR 2.096; 95% CI 1.413–3.109) in patients receiving GAP, an effect not observed with GC. Importantly, GAP conferred clinical benefit only in patients without PI3K pathway activation, while no survival advantage was seen in those with such alterations (Pinteraction=0.023 for PFS, Pinteraction=0.003 for OS). Similar results were obtained in the independent validation cohort treated with GAP (N=103) or GC (N=64) for BTC.

Conclusions

Genomic profiling using next-generation sequencing identified PI3K pathway activation as key molecular determinant that differentiates patient outcomes between GAP and GC treatments in advanced BTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineBiliary Tract NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansGemcitabineCisplatinPaclitaxelFemaleMaleMiddle AgedAgedAlbuminsAdultTumor Suppressor Protein p53MutationTreatment OutcomeProto-Oncogene Proteins p21(ras)Aged, 80 and over

Stichwörter der Autor:innen

Biliary tract neoplasmsGenomic analysisPI3K pathwaySystemic treatment

Substanzen

GemcitabineDeoxycytidineCisplatinPaclitaxel130-nm albumin-bound paclitaxelAlbuminsTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Otorhinolaryngology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Life Science, CHA University, Seongnam, Korea.
  • Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT
  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare
  • Yonsei University College of Medicine

Zitieren

APA

Kim, D., Sim, N. S., Woo, S., Kim, M. H., Lee, C. K., Hong, S. S., Kim, S. H., Hwang, H. K., Kang, C. M., Lee, W. J., Jo, J. H., Chung, T., Hwang, S., Kang, B., Kim, J. S., Kwon, C. I., Kim, S., Chon, H. J., Kim, C. G., …, & Choi, H. J. (2026). Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.1019

Vancouver

Kim D, Sim NS, Woo S, Kim MH, Lee CK, Hong SS, et al. Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2025.1019

BibTeX
@article{Kim2026,
  author = {Kim, Daeseong and Sim, Nam Suk and Woo, Seonjeong and Kim, Min Hwan and Lee, Choong-Kun and Hong, Seung Soo and Kim, Sung Hyun and Hwang, Ho Kyoung and Kang, Chang Moo and Lee, Woo Jung and Jo, Jung Hyun and Chung, Taek and Hwang, Sohyun and Kang, Beodeul and Kim, Jung Sun and Kwon, Chang-Il and Kim, Sangwoo and Chon, Hong Jae and Kim, Chang Gon and Park, Young Nyun and Choi, Hye Jin},
  title = {Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  doi = {10.3350/cmh.2025.1019}
}
Kostenlos starten →